Skip to main content
NewslettersWatchlist

Sage Therapeutic Com(SAGE-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low12.93
Day High13.61
Open:12.93
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
GlobeNewswire
ZURZUVAE™ (zuranolone) CIV, a Landmark Oral Treatment for Women with Postpartum Depression (PPD), is Now Available in the U.S.
Motley Fool
Why Sage Therapeutics Stock Sank Today
PR Newswire
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sage Therapeutics, Inc. - SAGE
Motley Fool
Is Sage Therapeutics Stock in Trouble After Dropping 50% in a Month?
PR Newswire
SAGE INVESTIGATION NOTICE: Robbins Geller Rudman & Dowd LLP Announces Investigation into Sage Therapeutics, Inc. and Encourages Investors with Substantial Losses or Witnesses with Relevant Information to Contact the Firm
PR Newswire
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sage Therapeutics, Inc. - SAGE
Motley Fool
Why Shares of Sage Therapeutics Slumped This Week
Motley Fool
2 Beaten-Down Stocks That Still Aren't Worth Buying
PR Newswire
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sage Therapeutics, Inc. - SAGE
Motley Fool
Is Sage Therapeutics a Contrarian Buy?
Motley Fool
Why Sage Therapeutics Stock Is Crashing Today
GlobeNewswire
FDA Approves ZURZUVAE™ (zuranolone), the First and Only Oral Treatment Approved for Women with Postpartum Depression, and Issues a Complete Response Letter for Major Depressive Disorder
Motley Fool
Why Sage Therapeutics Stock Is Tumbling Today
Business Wire
Sage Therapeutics to Present at Upcoming May Investor Conferences
Business Wire
Sage Therapeutics Announces First Quarter 2023 Financial Results and Highlights Pipeline and Business Progress
Business Wire
Sage Therapeutics to Report First Quarter 2023 Financial Results on Tuesday, May 2, 2023
Business Wire
Sage Therapeutics to Present at the Stifel 2023 CNS Days
ACCESSWIRE
Sage Potash Announces Exchange Listing
Business Wire
Sage Therapeutics Appoints Jessica Federer to Board of Directors
Business Wire
Sage Therapeutics and Biogen Share Update on FDA Advisory Committee for Zuranolone
Business Wire
Sage Therapeutics to Present at the Cowen 43rd Annual Health Care Conference
Business Wire
Sage Therapeutics Announces European Medicines Agency Granted SAGE-718 Orphan Drug Designation for the Treatment of Huntington’s Disease
Business Wire
Sage Therapeutics Announces Fourth Quarter and Full Year 2022 Financial Results and Highlights Pipeline and Business Progress
Business Wire
Sage Therapeutics and Biogen Announce FDA Accepts Filing of New Drug Application and Grants Priority Review of Zuranolone in the Treatment of Major Depressive Disorder and Postpartum Depression
Business Wire
Sage Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on Thursday, February 16, 2023
Business Wire
Sage Therapeutics to Provide Update on 2023 Key Initiatives at 41st Annual J.P. Morgan Healthcare Conference
Business Wire
Sage Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023
Business Wire
Sage Therapeutics and Biogen Complete Rolling Submission of New Drug Application for Zuranolone in the Treatment of Major Depressive Disorder and Postpartum Depression
Business Wire
Sage Therapeutics to Present at the Piper Sandler 34th Annual Healthcare Conference
Business Wire
Sage Therapeutics and Biogen to Host Investor Webcast on December 6, 2022 to Discuss Potential Commercialization Plans for Zuranolone
PR Newswire
Greater Prevalence of Anxiety & Depressive Disorders Driving Demand for New Anti-Anxiety Drug Candidates
Business Wire
Sage Therapeutics to Present at the Stifel 2022 Healthcare Conference

Profile

SAGE Therapeutics Inc. is a biopharmaceutical company developing and commercializing medicines to treat life-threatening central nervous system (CNS) disorders. The Company provides treatments for schizophrenia, major depressive disorder, pain, and traumatic brain injury conditions. Its initial product candidates include SAGE-547, SAGE-689 and SAGE-217. SAGE Therapeutics, Inc. is based in Cambridge, Massachusetts.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2024 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.